CryoCath "encouraged" by cryotherapy trial data:
This article was originally published in Clinica
Trial data have shown that CryoCath Technologies' catheter cryotherapy system is safe and feasible for treating focal atherosclerosis in peripheral arteries. A 15-patient trial assessed the Quebec, Canada firm's 7 French PermaFrost catheter using a double balloon centering system with a 20mm cooling section between the balloons. It showed that 9 of 11 patients had "symptomatic improvement". All but one of the nine patients had normal pedal artery pulses at follow-up, reported lead researcher Jean-Francois Tanguay, of Canada's Montreal Heart Institute.